Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Adebrelimab as Neoadjuvant Therapy in Resectable Locally Advanced ESCC
ChiCTR2600118795Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacituzumab tirumotecan and adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response (pCR) Rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanadebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600118795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118795.